S3-E26.3 - Advancing NASH Best Practices In NITs: Optimizing a NASH Biomarker Set
Send us Fan Mail This conversation starts with Roger Green asking Quentin Anstee to clarify exactly what he means by "stacking" variables. Quentin's reply: multiple measures to confirm the same endpoi...
29 Touko 202213min
S3-E26.2 - Advancing NASH Best Practices In NITs: "Stacking" NASH Biomarkers
Send us Fan Mail This conversation starts with Quentin Anstee complimenting Stephen Harrison for his observation that when we analyze NASH Biomarkers, we should consider the value of sustained respons...
28 Touko 202214min
S3-E26.1 - Advancing NASH Best Practices In NITs: Quentin Anstee's Five Key Takeaways
Send us Fan Mail This conversation starts with Quentin Anstee sharing the five key takeaways for NITs in general and NIT Best Practices he developed while preparing recent talks for the Liver Forum an...
28 Touko 202214min
S3-E26 - What Are We Learning About Clinical Trial Best Practices For NITs?
Send us Fan Mail Quentin Anstee joins Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green to share recently developed insights about NITs and what the clinical trial best practices ar...
26 Touko 202255min
S3-E25.6 - Emerging Concepts In NASH: NAFLD Patient Screening, NASH Management
Send us Fan Mail This conversation is centered on Marcelo Kugelmas's portion of Madrigal's disease-focused presentation at the Chronic Liver Disease Foundation's LiverConnect meeting this past March i...
22 Touko 202225min
S3-E25.5 - Emerging Concepts in NASH: Fatty Liver Pathophysiology, Epidemiology, Co-Morbidities
Send us Fan Mail This conversation is centered on Mazen Noureddin's portion of Madrigal's disease-focused presentation at the Chronic Liver Disease Foundation's LiverConnect meeting this past March in...
22 Touko 202221min
S3-E25.4 - NASH Drug Development in 2022: Will Quality of Life Data Help NASH Drugs Over the Finish Line?
Send us Fan Mail Louise Campbell starts this discussion by citing her sources of optimism about NASH drug development: (i) the high likelihood of getting a drug to market over the next couple of years...
22 Touko 202213min
S3-E25.3 - Future NASH Drug Development: More Diverse Trial Populations and More Study of Combination NASH Drugs
Send us Fan Mail This conversation is part of a broader overview of NASH drug development in 2022, led by Stephen Harrison and Jörn Schattenberg. It starts with Louise Campbell asking whether design a...
21 Touko 202214min
